Veopoz Market Report 2026

Veopoz Market Overview

• The Veopoz market growth in the historic period has been driven by improved understanding of complement-mediated diseases, availability of monoclonal antibody engineering platforms • Market expansion is supported by expansion of personalized immunotherapy approaches, rising investments in complement biology research • Growth Driver: Increase In Demand For Personalized Medicine Fueled By Advancements In Genomics And Biotechnology • Market Trend: Expansion Of Indications And Approvals Drive Growth In Rare Disease Treatments • North America was the largest region in 2025.

What Is Covered Under Veopoz Market?

Veopoz (pozelimab-bbfg) refers to a human monoclonal IgG4 antibody that selectively targets and inhibits complement factor C5 in the complement pathway. It helps to modulate immune responses in diseases where complement dysregulation plays a key role, such as in paroxysmal nocturnal hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). This targeted approach aims to reduce tissue damage and improve patient outcomes in these rare and ultra-rare conditions. The main indications in the veopoz market are gastrointestinal symptoms, hypoalbuminemia, edema, hypogammaglobulinemia, and malnutrition. Gastrointestinal symptoms refer to signs or conditions related to the digestive system, such as nausea, vomiting, diarrhea, or abdominal pain. Veopoz is used to treat gastrointestinal symptoms in patients with conditions such as short bowel syndrome. The various distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies and several end users including adult patients and pediatric patients.

What Is The Veopoz Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of personalized immunotherapy approaches, rising investments in complement biology research, growing adoption of precision medicine in rare diseases, increasing healthcare spending on orphan drugs, advancement of next-generation biologics manufacturing. Major trends in the forecast period include expanding use of complement inhibitors in rare diseases, growing focus on targeted monoclonal antibody therapies, increasing clinical emphasis on complement pathway modulation, rising adoption of precision diagnostics for rare disorders, strengthening regulatory support for orphan drugs.

Global Veopoz Market Segmentation

1) By Indication: Gastrointestinal Symptoms, Hypoalbuminemia, Edema, Hypogammaglobulinemia, Malnutrition 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End User: Adult Patients, Pediatric Patients

What Is The Driver Of The Veopoz Market?

The increase in demand for personalized medicine is expected to drive the growth of the veopoz market going forward. Personalized medicine (also known as precision medicine) refers to a medical approach that tailors treatment and healthcare decisions to the individual characteristics of each patient. The demand for personalized medicine is due to advancements in genomics and biotechnology, enabling more targeted and effective treatments that improve patient outcomes and minimize side effects. Veopoz (Pozelimab-bbfg) helps as a personalized medicine by selectively targeting and inhibiting complement factor C5 activation, allowing for tailored treatment based on individual patient profiles, genetic factors, and disease severity in complement-mediated conditions. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based healthcare organization for promoting the understanding and adoption of personalized medicine concepts, in 2023, personalized medicines accounted for over one-third of Food and Drug Administration (FDA) drug approvals for the fourth consecutive year, including 16 new treatments for rare diseases, more than double the six approved in 2022. Therefore, the increase in demand for personalized medicine is driving the growth of the veopoz industry.

Key Players In The Global Veopoz Market

Major companies operating in the veopoz market are Regeneron Pharmaceuticals Inc.

Global Veopoz Market Trends and Insights

The key trend in the veopoz market is expanding approvals for other indications to enhance the drug's market reach and therapeutic applications. Expanding the approved indications will help the company address a broader patient population and increase its market share in the biologics and immunology space. For instance, in August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval from the Food and Drug Administration (FDA) for Veopoz as the first treatment for CHAPLE disease, an ultra-rare hereditary disorder that affects both adults and children aged one year and older. Veopoz is a fully human monoclonal antibody specifically designed to target complement factor C5, aiming to regulate this overactive immune response. The approval marks a significant milestone for Regeneron Pharmaceuticals, their tenth FDA-approved medicine, and addresses critical pre-approval inspection issues related to another product.

What Are Latest Mergers And Acquisitions In The Veopoz Market?

In August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company manufacturing Veopoz, partnered with Orsini Specialty Pharmacy. Through this partnership, Orsini became Veopoz's exclusive specialty pharmacy. This collaboration also enables Orsini to support patients with ultra-rare conditions, offering a life-changing treatment previously unavailable. Orsini Specialty Pharmacy is a US-based independent specialty pharmacy focused on rare diseases and gene therapies.

Regional Insights

North America was the largest region in the veopoz market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Veopoz Market?

The veopoz market consists of sales of Veopoz (pozelimab) injection and companion medications for autoimmune diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Veopoz Market Report 2026?

The veopoz market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the veopoz industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.